Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12779MR)

This product GTTS-WQ12779MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12779MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1747MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ2813MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ1954MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ7571MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ8908MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ6937MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ5959MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ273MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 17-1A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW